what is microdosing glp-1 GLP-1? Full Guide THE GLP-1 MICRODOSING PROGRAM

10.1159/000480525 [DOI] [PMC free article] [PubMed] [Google Scholar] 3.Gatineau M et al (2014) Adult obesity and type 2 diabetes

There was no significant change in BMI within the exenatide group at 12 weeks, indicating that the effect on intracranial pressure was not driven by reduction in body weight, but likely by direct effect of exenatide to modulate intracranial pressure at the choroid plexus

Tumours release adrenomedullin and IL-6 which can cause hepatic insulin resistance and -cell dysfuction resulting in paraneoplastic diabetic syndrome

And unlike tirzepatide or semaglutide, phentermine is not a GLP-1 agonist , so it does not provide the metabolic and glycemic benefits that incretin-based therapies deliver

Footnotes These authors contributed equally: Zhikai Zheng, Yao Zong References 1.Marzook, A., Tomas, A